Where are you?

To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.


Our latest product candidate delivers targeted and controlled bone formation.

Fibrin-PTH (KUR-113) promotes bone formation through the induction of osteoprogenitor cell differentiation, enhancement of osteoblast proliferation and by increasing the lifespan of bone-forming cells. Fibrin-PTH (KUR-113) is entering Phase 2 clinical trials for spine fusion in humans.

Fibrin-PTH (KUR-113) is the first ever investigational drug-biologic product candidate being evaluated for spinal fusion.#



This product candidate is based on the well-established mechanism of action of parathyroid hormone – or PTH as it is commonly known – and the natural healing matrix fibrin. Using its proprietary technology, a modified PTH is covalently bound to fibrin through the TG-Hook peptide linker, which also contains a site for enzyme-mediated release of PTH.1

Watch to find out how Fibrin-PTH (KUR-113) can achieve spinal fusion through prolonged and controlled delivery of PTH from a single application in the spine.

Comparable efficacy to rhBMP-2

Demonstrated for Fibrin-PTH (KUR-113) in preclinical animal studies of spinal fusion.2*#

Easy to use

Excellent flowability and setting properties for Fibrin-PTH (KUR-113) in preclinical studies.3*#

Clinical experience

Effective for bone healing with a promising safety profile in two Phase 2 orthopedic trauma trials.4,5

Ready for Phase 2

Fibrin-PTH (KUR-113) is entering Phase 2 clinical trials for spine fusion in humans.6

Clinical evidence from bone healing indications


Tibial shaft fractures


Tibial plateau fractures

Learn more about our innovations

For further information send us your details and we will be in touch.